Poolbeg Pharma A.I. Unlocking the power of unique human challenge trial data

Poolbeg Pharma A.I. Unlocking the power of unique human challenge trial data

Poolbeg Pharma (LON:POLB) Chief Executive Officer Jeremy Skillington talks us through the Poolbeg September 2023 company presentation.

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), is a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need.

Share on:
Find more news, interviews, share price & company profile here for:
Poolbeg Pharma's CEO, Jeremy Skillington, will present at major industry conferences in March and April 2025, showcasing innovative therapies and advancements.
Poolbeg Pharma (LON:POLB) secures a crucial patent for POLB 001 in South Korea, enhancing its portfolio for treating severe influenza and other conditions.
HOOKIPA Pharma and Poolbeg Pharma enter talks for a potential acquisition aimed at developing next-generation immunotherapies for critical medical needs.
Poolbeg Pharma and HOOKIPA Pharma propose a new collaboration with Gilead Sciences set to invest up to $8.7495 million, pending further negotiations.
Los Consejos de Poolbeg Pharma y HOOKIPA Pharma anuncian el respaldo de Gilead para una posible oferta y la actualización de su recaudación de fondos.
Poolbeg Pharma and HOOKIPA Pharma confirm Gilead Sciences' support for participation in a $30 million+ private placement fundraise amid potential merger talks.

Search

Search